{"name":"Steno Diabetes Center Copenhagen","slug":"steno-diabetes-center-copenhagen","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Metabolic","slug":"metabolic","revenue":0,"percentOfTotal":0,"drugCount":4,"colorKey":"cardiovascular","drugs":[{"name":"Low-Dose Glucagon","genericName":"Low-Dose Glucagon","slug":"low-dose-glucagon","indication":"Acute hypoglycemia in patients with diabetes mellitus","status":"marketed"},{"name":"Placebo-Metformin","genericName":"Placebo-Metformin","slug":"placebo-metformin","indication":"Type 2 diabetes mellitus","status":"marketed"},{"name":"Placebo-Repaglinide","genericName":"Placebo-Repaglinide","slug":"placebo-repaglinide","indication":"Type 2 diabetes mellitus","status":"marketed"},{"name":"insulin aspart + insulin aspart protamin","genericName":"insulin aspart + insulin aspart protamin","slug":"insulin-aspart-insulin-aspart-protamin","indication":"Type 1 diabetes mellitus","status":"marketed"}]},{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":2,"colorKey":"oncology","drugs":[{"name":"Glucose-Dependent Insulin-Releasing Hormone[3-30]","genericName":"Glucose-Dependent Insulin-Releasing Hormone[3-30]","slug":"glucose-dependent-insulin-releasing-hormone-3-30","indication":"Other","status":"phase_1"},{"name":"LOKELMA 5 GM Powder for Oral Suspension","genericName":"LOKELMA 5 GM Powder for Oral Suspension","slug":"lokelma-5-gm-powder-for-oral-suspension","indication":"Hyperkalemia (elevated serum potassium levels)","status":"marketed"}]},{"name":"Cardiovascular","slug":"cardiovascular","revenue":0,"percentOfTotal":0,"drugCount":2,"colorKey":"immunology","drugs":[{"name":"Irbesartan treatment","genericName":"Irbesartan treatment","slug":"irbesartan-treatment","indication":"Hypertension","status":"phase_3"},{"name":"Spironolacton (hexalacton(R))","genericName":"Spironolacton (hexalacton(R))","slug":"spironolacton-hexalacton-r","indication":"Heart failure with reduced ejection fraction","status":"marketed"}]}],"pipeline":[{"name":"Glucose-Dependent Insulin-Releasing Hormone[3-30]","genericName":"Glucose-Dependent Insulin-Releasing Hormone[3-30]","slug":"glucose-dependent-insulin-releasing-hormone-3-30","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Irbesartan treatment","genericName":"Irbesartan treatment","slug":"irbesartan-treatment","phase":"phase_3","mechanism":"Irbesartan blocks angiotensin II type 1 receptors, reducing vasoconstriction and aldosterone secretion to lower blood pressure.","indications":["Hypertension","Diabetic nephropathy in patients with type 2 diabetes"],"catalyst":""},{"name":"LOKELMA 5 GM Powder for Oral Suspension","genericName":"LOKELMA 5 GM Powder for Oral Suspension","slug":"lokelma-5-gm-powder-for-oral-suspension","phase":"marketed","mechanism":"Lokelma (sodium zirconium cyclosilicate) is a potassium binder that traps potassium in the gastrointestinal tract and increases fecal potassium excretion.","indications":["Hyperkalemia (elevated serum potassium levels)"],"catalyst":""},{"name":"Low-Dose Glucagon","genericName":"Low-Dose Glucagon","slug":"low-dose-glucagon","phase":"marketed","mechanism":"Low-dose glucagon activates glucagon receptors to stimulate hepatic glucose output and counteract hypoglycemia in diabetes patients.","indications":["Acute hypoglycemia in patients with diabetes mellitus"],"catalyst":""},{"name":"Placebo-Metformin","genericName":"Placebo-Metformin","slug":"placebo-metformin","phase":"marketed","mechanism":"Metformin reduces hepatic glucose production and improves insulin sensitivity, thereby lowering blood glucose levels in type 2 diabetes.","indications":["Type 2 diabetes mellitus"],"catalyst":""},{"name":"Placebo-Repaglinide","genericName":"Placebo-Repaglinide","slug":"placebo-repaglinide","phase":"marketed","mechanism":"Repaglinide is a meglitinide that stimulates insulin secretion from pancreatic beta cells by closing ATP-sensitive potassium channels.","indications":["Type 2 diabetes mellitus"],"catalyst":""},{"name":"Spironolacton (hexalacton(R))","genericName":"Spironolacton (hexalacton(R))","slug":"spironolacton-hexalacton-r","phase":"marketed","mechanism":"Spironolactone is a potassium-sparing diuretic and aldosterone antagonist that blocks aldosterone receptors in the collecting duct of the kidney to reduce sodium reabsorption and increase potassium retention.","indications":["Heart failure with reduced ejection fraction","Hypertension","Primary hyperaldosteronism","Edema associated with cirrhosis or nephrotic syndrome"],"catalyst":""},{"name":"insulin aspart + insulin aspart protamin","genericName":"insulin aspart + insulin aspart protamin","slug":"insulin-aspart-insulin-aspart-protamin","phase":"marketed","mechanism":"This is a biphasic insulin formulation combining rapid-acting insulin aspart with intermediate-acting insulin aspart protamine to provide both immediate and sustained blood glucose control.","indications":["Type 1 diabetes mellitus","Type 2 diabetes mellitus"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMiYEFVX3lxTFBKSDAzalY3NmwyOERrNGdDR2I4Z0s1VnBWNGFON3ZBWllqNjdCQm9KdjQtbk43WGFWd0tKLXNONmJqYkc1T05sUzVjLVVQd19UNVpoaTJHeWw2Vkx2OWxyUg?oc=5","date":"2026-03-27","type":"pipeline","source":"JACC Journals","summary":"Effects of Finerenone on Heart Failure Outcomes According to Baseline Heart Failure Risk in Chronic Kidney Disease and Type 2 Diabetes - JACC Journals","headline":"Effects of Finerenone on Heart Failure Outcomes According to Baseline Heart Failure Risk in Chronic Kidney Disease and T","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMipgFBVV95cUxOVzhkU3hjZjhHVFBUN1RrS0pfQkFCVlBUUVlIQnpUdVlSYjd2SU9VZkxTOVc3STFwY3VLeWxsbEVQNDZfM3J3Qk11b0hhODJFUDkyb3JONlh3b3hiSXFianVoLVhQVGh2Ml9SbUFYWlkwR01mQUd4UzBZWlRkdThkSjZVVC1rVGF0elFIWUNoLWxtOXpxTHl0M1dUQkhCYTFtX1BzV1F3?oc=5","date":"2026-01-22","type":"pipeline","source":"Medscape","summary":"Empagliflozin Benefits Patients With Rare Genetic Diabetes - Medscape","headline":"Empagliflozin Benefits Patients With Rare Genetic Diabetes","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMid0FVX3lxTFAtbU9Nc2pfSk5FODlLRFpZc2pHRk45NzdvZGY3S0d6YzlhakFOdzV6RjBJeHpZVjd2S3I1VVUyd05oNDdOZ2ZIVTBFWnFpLU9FaWlPamdzeWdsZ0xCNUZfWTVYd2pzTFIzczBPMGRwZ3hMcnprdXpz?oc=5","date":"2025-11-21","type":"regulatory","source":"Market Data Forecast","summary":"Semaglutide Market Size, Share, Growth & Trends Report, 2033 - Market Data Forecast","headline":"Semaglutide Market Size, Share, Growth & Trends Report, 2033","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMizwFBVV95cUxPNV9ZekVRaVROTXNLQ0JiYllxd3dEeF80UzZhakxCZ2h4R2pVajdGSzRzX080eDRxT3VTRG4teXJDWlR6d2xpUlpidUpXZ29raHRtMVdaRnRYM1BvMm8yNzhKTGNHSDhHMWZJdHJndTZlelFyRDhQX29namhTaGw1eFc5Rk9GVmxhRHREUU40V0FhakZtbW0yTTJTcHd5X2Vnb3Q4alBmSHBSTl9sbnJ4LWxNVUNuNGszTzdXYzFROW1Wb2o1WW9lVGphT3NhYVE?oc=5","date":"2024-10-25","type":"pipeline","source":"European Medical Journal","summary":"Screening and Monitoring for Presymptomatic Type 1 Diabetes: The DiaUnion Project - European Medical Journal","headline":"Screening and Monitoring for Presymptomatic Type 1 Diabetes: The DiaUnion Project","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMia0FVX3lxTE9JaHFNNFNRZ1RZYnJfUC1nZVZiSy1iWF9yeF9oTkNwdUQ0Um9NQ1RtTm4tNWk2ZnI3UTZKV1lVdmJUX0NPYnhRbVJBRF83RUNwZmRPbU5KV3MxQWtwYk9vclBjQlVSWWpFZTFr?oc=5","date":"2024-09-03","type":"pipeline","source":"Wiley Online Library","summary":"Finerenone and left ventricular hypertrophy in chronic kidney disease and type 2 diabetes - Wiley Online Library","headline":"Finerenone and left ventricular hypertrophy in chronic kidney disease and type 2 diabetes","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiuAFBVV95cUxPZ21QR0dKblVnUUhrdGdpWHh2WTdpU21DczNKalBQQ2ppS3ZpQjV1Tjk2YXEza01GS3N1Yl9hbnlxdTQ1Y3U0TE1tb050LTExMWpNbHFGTHAyTHdfNWdpd2RtWUJKWEFKOWFyb0lrbDlDYUltZ3BsZ2x6Zlo5QktCU2FBYzk5TWJvaS1nX2hjVWlJcHZzMndaUFRzVzF4ZUdiY0xlTjRFa2dXYTF6TEhRY0pFSGdyenk5?oc=5","date":"2024-06-24","type":"regulatory","source":"Pharmacy Times","summary":"Results From the FLOW Trial Show Benefits of Semaglutide on Chronic Kidney Disease - Pharmacy Times","headline":"Results From the FLOW Trial Show Benefits of Semaglutide on Chronic Kidney Disease","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiX0FVX3lxTE9kbU1rTFJCWkY0NE1wMDVVNFEzb1djZl8yQXNrbU9qdW5lV1lUcm5EUnBhbTNhSHpZcXZZVjBjYlFjT19icWlRdDVQS1lsMUFubXdTd0dxampUWk4xd1BF?oc=5","date":"2024-06-24","type":"regulatory","source":"nature.com","summary":"Effects of semaglutide with and without concomitant SGLT2 inhibitor use in participants with type 2 diabetes and chronic kidney disease in the FLOW trial - nature.com","headline":"Effects of semaglutide with and without concomitant SGLT2 inhibitor use in participants with type 2 diabetes and chronic","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMikgFBVV95cUxPQnpXaWxPV2tzelZ4YzVwNnNlb0hrbER0cHRIbEp1cUJKX2tTYjFZMnlYSmMzR1lQa01VNUVQa0JmOTVaTVpjSXd0TDA2dS1GeUkxME9UOWpBM245ZGI4ZldQUkJvRUxDdjZFTlp6N2xvQ2h5d2FaY21kVXA2U1RzWUcyN1N6Mm9LcmV2Yy1zMFNHQQ?oc=5","date":"2023-01-17","type":"pipeline","source":"labiotech.eu","summary":"Is Copenhagen the world capital of life science? - labiotech.eu","headline":"Is Copenhagen the world capital of life science?","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMickFVX3lxTE42ZHFFTjNPdE1aRjlNaGpTTWJuLWd4S1lqZWVuSU5NT3hyVVFaYjdKU0g1cV9yckhUemI1U1RweDZoODl5d0dDV3J2LTRrdjBqTmVYVGJXcDh0bzBOZ0hoRi1xaG9YQ210VWhjV2RucWU5Zw?oc=5","date":"2022-02-09","type":"pipeline","source":"medrxiv.org","summary":"Precision Diagnostic Approach to Predict 5-year Risk for Microvascular Complications in Type 1 Diabetes - medrxiv.org","headline":"Precision Diagnostic Approach to Predict 5-year Risk for Microvascular Complications in Type 1 Diabetes","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMipgFBVV95cUxOTGpmWnpsYVhxSklPclJJa3ZGQzY5ajNwRzhmTGRrNy02THY3Rzl4dmd1N2UtUkYzUklfV3JIamUyY3RwQlZpOWRZcjB2bFpjbUh5MXd0QlJydTFNMGZvY2hFbGZOUmZEZ3pCRGk2REJxM3doeGZHOC1CNm5ZaUg5anlfSnVxU1lEZFVZanc5SS1iVnZhNW5LZWNMVks4VFFYQVNnY0Rn?oc=5","date":"2021-02-03","type":"pipeline","source":"Novo Nordisk Fonden","summary":"Mads Krogsgaard Thomsen appointed as new CEO of the Novo Nordisk Foundation - Novo Nordisk Fonden","headline":"Mads Krogsgaard Thomsen appointed as new CEO of the Novo Nordisk Foundation","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMixAFBVV95cUxOT3RqWXIzTjZ2OWVtVEJRNzRQVzVkc1dJN3hkcjZjUG9IM01McUFGSmo4bDJvaHE4N3BSU0NuR0xJVVlRYUlZNmVKYVkwMldUSjhmdFY2OTNXZEUwd3BxVVNhUUJUakxRcXFKNUZLYWdTYnBtZnBvTjY0b2NFNTJfMnFrZkExWTNBMVVoaFBEX2ZHYUl4UDZvaUh1S2NsME9laHFOTmctVHZFb2luRXdRMmNRV09aMkJtTHRxb0Rzd0V1anlI?oc=5","date":"2020-04-02","type":"pipeline","source":"Healio","summary":"Urinary biomarker pattern may predict progression of CKD in type 2 diabetes - Healio","headline":"Urinary biomarker pattern may predict progression of CKD in type 2 diabetes","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiuwFBVV95cUxPZnNuR2QwT1dEWHpoVVRhNlZqYkpXQTUzREM5VUxjbThReWUwRnVORkdxcHMyZVQyaV9xZU1LcXA3RjBhMVBwRmFfLXBWVTJ6cmNmbklZMW82aEJzSWdWdzMzOUs5NUZhNjdrZE9wbjMzcDlDbzI3aE05czV4QU1zTGRDcW9DT3d5N1gwSGRQMDU5RkZJRkNiektmWXdid1F4Y19MUU8wM2RVUDY0MERqZ3BYc2NHOEhpRFFn?oc=5","date":"2017-09-13","type":"pipeline","source":"Fierce Pharma","summary":"EASD: Novo Nordisk's combo Xultophy beat rivals at cutting LDL, blood pressure - Fierce Pharma","headline":"EASD: Novo Nordisk's combo Xultophy beat rivals at cutting LDL, blood pressure","sentiment":"neutral"}],"patents":[],"drugCount":8,"phaseCounts":{"phase_1":1,"phase_3":1,"marketed":6},"enrichmentLevel":2,"visitCount":4,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}